RxDoctor Payments Data

Shilpa Kauta, MD

Neurology · Newark, DENPI 1649434283

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,450 of the $6,771 with a category attached, or 65.7%. Jazz Pharmaceuticals Inc. accounts for 63.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $2,290 and has fallen 87.9% since, to $277 in 2025.

$6,771in general payments, 2019–2025

Across 27 payments — averaging $250.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$4K
  • Inspire Medical Systems, Inc.$2K
  • Avadel CNS Pharmaceuticals, LLC$229
  • Eisai Inc.$125
  • Harmony Biosciences LLC$62
  • Sunovion Pharmaceuticals Inc.$36
  • plus $80 from 4 others

What the payments were for

  • Consulting fees$4,45066%
  • Travel & lodging$1,35420%
  • Food & beverage$96614%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,771 in reported general payments places this provider in the 85th percentile of 61 neurology providers in Delaware.

See all neurology providers in Delaware

Medicare billing

Part B allowed, 2024
$76,337
Medicare patients
489
Services billed
935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl16$111,759
HorizantGabapentin Enacarbil11$8,333
QuviviqDaridorexant Hcl16$7,689
DayvigoLemborexant18$5,402
Pramipexole ErPramipexole Di-Hcl17$5,108
Gabapentin212$3,261
Pramipexole DihydrochloridePramipexole Di-Hcl95$1,679
Pregabalin66$1,467
Ropinirole ErRopinirole Hcl17$1,018
Clonazepam87$973
Methylphenidate ErMethylphenidate Hcl12$941
Eszopiclone29$878
Ropinirole Hcl37$873
Modafinil14$510
Methylphenidate Hcl21$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$62$111,75916 claims
Eisai Inc.Dayvigo$125$5,40218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 61 neurology providers in Delaware.

Other neurology in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →